Core Insights - Mirum Pharmaceuticals has completed enrollment in the phase III EXPAND study for Livmarli, targeting cholestatic pruritus in patients aged six months and older with rare cholestatic liver diseases, including biliary atresia [1][8] - The study aims to support potential label expansion for Livmarli, with top-line data expected in Q4 2026 [2][8] - Livmarli, an orally administered IBAT inhibitor, is currently approved for treating cholestatic pruritus in patients with Alagille syndrome and certain patients with progressive familial intrahepatic cholestasis [3][4] Company Performance - Mirum's shares have increased by 17.3% year to date, outperforming the industry average rise of 2.8% [5] - Livmarli's net product sales reached $360 million in 2025, reflecting a 68.8% year-over-year increase, driving the company's revenue growth [9] - The acquisition of Travere Therapeutics' bile acid products has diversified Mirum's revenue stream, with revenues from these products totaling $161.3 million, up 31% year over year in 2025 [10] Future Outlook - Mirum anticipates worldwide net product sales of approximately $630-$650 million in 2026, driven by strong sales of Livmarli and other marketed products [11]

Group 1: Netflix - Netflix has been a core holding and recently saw a price dip, which presents a buying opportunity around the $75 range [2][3] - The company is expected to walk away from a merger deal with Warner Brothers, which is viewed as a positive move that will enhance its competitive position in Hollywood [4] - The stock is anticipated to recover to around $125 as Netflix continues to dominate the market [4] Group 2: Eli Lilly - Eli Lilly is highly regarded for its GLP-1 drugs, with an upcoming approval for a new pill that is expected to be more effective than competitors [5][6] - The company is positioned to dominate the weight loss drug market, especially with the introduction of GLP-3 next year [7][8] - Eli Lilly is seen as having superior management and products compared to its main competitor, Novo Nordisk [8] Group 3: Micron and Nvidia - Micron shares have increased over 40% in 2026, but there is a belief that the stock is still undervalued due to market doubts about AI growth [9][10] - Micron's earnings are projected to rise significantly, with estimates suggesting earnings could reach over $30 per share, indicating a strong upside potential [10][11] - Nvidia is also viewed as undervalued, trading at a low multiple compared to its historical average, presenting a significant investment opportunity [12][13] Group 4: Tesla - Tesla is currently facing challenges, with a noted lack of focus on its EV business and a shift towards battery storage as its standout segment [15][16] - The company's future reliance on autonomous vehicle technology is questioned, with concerns about its economic viability [17][18] - The stock is perceived to be overvalued, with a suggested fair value around $200, indicating a tough investment outlook [18]

Core Insights - Indivior Pharmaceuticals Inc. announced a survey revealing significant gaps in the availability of medications for opioid use disorder (MOUD) in U.S. correctional facilities [1][2] Group 1: Survey Findings - The survey, conducted in partnership with the National Commission on Correctional Health Care, included 212 jails, prisons, and detention centers, finding that only 58% offer at least one FDA-approved MOUD [2] - Jails are more than twice as likely to provide MOUD compared to prisons, with facilities in the West having over three-fold higher odds of offering MOUD than those in the Midwest [3] - The South reports the lowest rates of treatment access, with fewer than 10% of diagnosed individuals receiving treatment, while Midwest facilities show moderate levels of treatment, with some below 10% and others between 20%-29% [3] Group 2: Urgency for Change - The study emphasizes the need for integrating evidence-based care into correctional facilities, highlighting that 17% of individuals in state prisons and 19% in jails meet the criteria for opioid use disorder [4] - Individuals in their first two weeks post-release face overdose mortality rates up to 40 times higher than the national average, indicating the critical need for MOUD treatment during incarceration [4] Group 3: Recommendations for Improvement - Respondents identified five key areas for improving MOUD continuity and outcomes, including housing and employment support, which are essential for sustaining recovery [6] - There is a call for greater investment in long-acting injectables and telehealth partnerships to extend care into rural settings [8] - Emphasis on the importance of pre-release planning and providing a warm handoff from incarceration to community-based MOUD services [8] Group 4: Barriers to Implementation - Despite the recognition of MOUD as the standard of care, facilities face barriers such as stigma, abstinence-only philosophies, lack of provider training, limited budgets, and geographic disparities in healthcare infrastructure [9]

Core Viewpoint - Eli Lilly's stock has faced pressure following a downgrade by HSBC, raising questions about the sustainability of its strong performance in the obesity drug market and whether investors should reassess valuations [1][3]. Stock Performance - The stock declined by 4.2% after the downgrade, although it remains one of the best-performing large-cap healthcare stocks over the past year, with a 14% increase in shares over the last 12 months, significantly outperforming Novo Nordisk, which has seen a decline of over 54% in the same period [2]. Valuation Concerns - HSBC analyst Rajesh Kumar downgraded Eli Lilly from "Hold" to "Reduce" and lowered the price target from $1,070 to $850, citing concerns that the stock may be overvalued relative to its fundamentals [3]. - The analyst noted that the stock is currently "priced to perfection," indicating that much of the optimism regarding Lilly's growth prospects is already reflected in its stock price [4]. Obesity Drug Market Outlook - HSBC revised its outlook for the total addressable market (TAM) for obesity drugs, projecting it to be between $80 billion and $120 billion by 2032, which is significantly lower than the consensus expectation of exceeding $150 billion [5]. - The downgrade reflects concerns about increasing pricing pressures and competition, particularly from Novo Nordisk, which produces Wegovy [6]. Competitive Dynamics - Analysts have warned that rising working capital intensity, pricing pressures, and rebate dynamics at both Eli Lilly and Novo Nordisk suggest that pricing dynamics may worsen [7]. - The divergence in market outlook between Lilly and Novo Nordisk has raised investor concerns, with Lilly's success in the cash-pay channel attributed more to pricing than product differentiation [8]. Pipeline Risks - While Eli Lilly is expanding its obesity drug portfolio, there are potential risks associated with upcoming products, such as the orforglipron pill, with expectations that compliance and persistence may disappoint [9]. - Current market estimates for 2026 revenue from the drug range from $1.1 billion to $1.3 billion, which are viewed as optimistic, especially given Lilly's $1.5 billion pre-launch inventory [10]. Analyst Sentiment - Despite HSBC's cautious stance, healthcare remains an attractive sector overall, described as relatively defensive amid macroeconomic uncertainty [11]. - The consensus among analysts remains positive for Eli Lilly, with 16 out of 19 analysts giving a buy rating, 2 a hold rating, and 1 a sell rating, indicating that the recent pullback may represent a buying opportunity [12].

Core Insights - CytomX Therapeutics (CTMX) shares surged 44.2% following positive phase I expansion data for its PROBODY ADC, varsetatug masetecan (Varseta-M), in late-line metastatic colorectal cancer (CRC) [1][5] Study Details - The study involved heavily pretreated patients, with a median of three prior metastatic therapies and 96% having prior irinotecan exposure. 76% of patients had liver metastases, and 71% carried KRAS mutations. All evaluable tumor biopsies showed high EpCAM levels [2] - In the phase I expansion portion of the CTMX-2051-101 study, 56 patients were evaluable for efficacy across three dose cohorts (7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg) with a median follow-up of about eight months. The overall response rates were 6% at 7.2 mg/kg, 20% at 8.6 mg/kg, and 32% at 10 mg/kg [3][5] Efficacy and Safety - Progression-free survival improved with dose escalation: 5.5 months at 7.2 mg/kg, 6.8 months at 8.6 mg/kg, and 7.1 months at 10 mg/kg. The overall disease control rate was 88% across the expansion population [4][5] - Varseta-M exhibited a generally manageable safety profile, with most treatment-related adverse events being mild to moderate. One severe acute kidney injury was reported, but no additional severe events were observed by the January 2026 data cutoff [7] Future Plans - CytomX plans to prioritize the 8.6 mg/kg and 10 mg/kg regimens for further evaluation and is working on dose-optimization efforts. The company aims to engage with the FDA regarding a potential registrational study for Varseta-M in advanced CRC [6][8] - Additionally, CytomX is exploring combination strategies, including a phase I study of Varseta-M with Roche's Avastin and a phase Ib/II study combining Varseta-M with Avastin and chemotherapy expected to begin by the end of 2026 [9]

Core Viewpoint - Novo Nordisk has faced significant challenges in the past year, including a CEO change, a halved share price, and reduced guidance due to increased competition in the GLP-1 drug market [1][5] Company Performance - The stock has seen a drastic decline, leading to a bearish sentiment among investors and analysts downgrading price targets [5] - Despite these challenges, Novo Nordisk remains a strong healthcare business with high margins and a solid product portfolio [6] Product Development - Novo Nordisk is developing a promising GLP-1 drug, UBT251, in collaboration with The United Laboratories International Holdings Limited, which showed an average weight loss of 19.7% after 24 weeks in a phase 2 trial [3] - The company is competing with Eli Lilly, which has a rival triple agonist drug, retatrutide, that achieved an average weight loss of 28.7% after 68 weeks [4] Investment Potential - The stock is currently trading at 11 times its trailing earnings, significantly lower than the S&P 500 average of 24, suggesting potential value for long-term investors [7] - There is optimism that if UBT251 can demonstrate effectiveness over a longer duration, it could enhance growth prospects for Novo Nordisk in the GLP-1 market [4]

Core Viewpoint - The current financial environment characterized by geopolitical tensions, rising Treasury yields, and declining equity markets has led investors to seek defensive positions, particularly in gold and specific ETFs that provide stability and reduced volatility [5][6][18]. Group 1: Gold and Defensive ETFs - SPDR Gold Trust (GLD) has been a strong performer in 2026, up over 16% year-to-date and 67% over the past year, highlighting gold's appeal as a safe-haven asset during times of uncertainty [3][7]. - GLD operates with a net expense ratio of 0.40% and has a long track record since its inception in 2004, making it a reliable option for direct commodity exposure [8]. - The iShares 20+ Year Treasury Bond ETF (TLT) offers a yield of approximately 4.3% and has over $45 billion in net assets, but it has recently declined by 2.5% due to rising yields, which compress bond prices [10][11]. - The iShares MSCI USA Min Vol Factor ETF (USMV) aims to provide equity exposure with lower volatility, managing to decline roughly 30% less than the S&P 500 during recent market pressures [15][16]. Group 2: Market Conditions and Investor Behavior - The VIX fear gauge has increased by over 54% in the past month, indicating heightened market uncertainty, while consumer sentiment remains low at 56.4 [5]. - Geopolitical tensions and tariff uncertainties have made defensive positioning essential, pushing investors towards gold, long-duration bonds, and low-volatility equities [6][18]. - The performance of TLT is contingent on the direction of long-term yields rather than just equity market movements, emphasizing the need for investors to understand the underlying dynamics [12].

Economic Overview - A deep recession has already started, with significant indicators pointing towards economic decline [1][2] - The National Bureau of Economic Research (NBER) defines a recession as two consecutive quarters of GDP decline, and current economic conditions suggest this definition may soon be met [2] Employment and Unemployment - February saw job losses of 92,000, with unemployment rising to 4.4%, indicating a troubling labor market [3] - The rising unemployment rate is expected to exert further pressure on consumer spending and economic growth [6] Inflation and Cost of Living - Inflation is on the rise, with gas prices projected to reach $4 per gallon within two weeks, up from $3.80 [3] - The increase in oil prices is expected to contribute to rising costs of everyday items, further eroding discretionary income for consumers [5] Housing Market - Home prices have remained flat to down over the last two years, with slow home sales attributed to high mortgage rates [7] - The stagnation in home equity is particularly impactful for older Americans, limiting their financial flexibility [7] Stock Market Dynamics - The stock market has experienced a downturn, with the leading stocks, referred to as the "Mag 7," already stumbling [6] - The overall market performance has been slightly down this year, contrasting with the previous years' gains [6]

Core Viewpoint - Eli Lilly's stock has experienced a decline following a downgrade by HSBC, which cited an "inflated market" for obesity drugs and deemed the stock appropriately priced [1] Group 1: Stock Performance - Eli Lilly's stock is currently trading at $967.06, down 2.2% after the downgrade [1] - The stock has a year-to-date deficit of 9.8%, but has gained over 17% in the last 12 months [3] - The 12-month consensus target price for Eli Lilly is $1,201.43, representing a 21.5% premium to current levels [2] Group 2: Analyst Ratings - A majority of analysts remain bullish on Eli Lilly, with 26 out of 30 firms rating it "buy" or better [2] - The recent downgrade by HSBC is notable given the overall positive sentiment from other analysts [1][2] Group 3: Options Market Sentiment - Options traders are leaning bearish, as indicated by a 10-day put/call volume ratio of 1.16, which is higher than 98% of annual readings [4] - The Schaeffer's put/call open interest ratio (SOIR) of 1.60 also ranks higher than all other readings from the past year, suggesting bearish sentiment [4] Group 4: Volatility Expectations - Options for Eli Lilly are currently considered affordable, with a Schaeffer's Volatility Index (SVI) of 37%, which ranks higher than 25% of all other readings from the past year [5] - This indicates that near-term option traders are pricing in relatively low volatility expectations [5]

Eli Lilly & Co. shares dip after HSBC turned bearish on the stock, for the second time in a year, saying investor expectations for weight-loss drugs are over inflated. https://t.co/wDBYf58raE ...